EntoPharm is clinical-stage biopharmaceutical company focusing on the discovery and development of bioactive peptides from insects for therapeutic application as anti-viral, anti-cancer and antibiotic drugs. Headquartered in Seoul, Korea, the company was established in February 2000 to explore the pharmaceutical capability of drug candidates originating from the immune systems of insects. The company's name, EntoPharm is a combination of the abbreviations of 'entomology' and 'pharmaceutical,' which indicate the specialized field of the company. With its broad research network in Russia and Europe, EntoPharm has discovered several drug candidates of huge potential. Among those products in development, the most advanced is Alloferon, a novel peptide that has demonstrated anti-viral and anti-tumor properties through its unique immunomodulatory mechanism. It is now undergoing phase Ⅱ clinical trials as a treatment for chronic genital herpes and acute hepatitis B and C in Russia. EntoPharm recently succeeded in purifying and synthesizing the S2, a modified peptide containing immunomodulating property and direct cytotoxicity against cancer cell, thus creating the opportunity to develop another peptide drug of oncological potential.